Regeneron Pharmaceuticals management check
REGN · Health Care · Biotechnology · CEO Leonard S. Schleifer
Filings as of
Closest peers in Biotechnology
- 38GILDGilead Sciences83
- 50VRTXVertex Pharmaceuticals81
- 88REGNRegeneron Pharmaceuticals77
- 111AMGNAmgen76
- 208ABBVAbbVie68
- 300INCYIncyte61
- 405MRNAModerna53
- 439BIIBBiogen48
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
2432ndDetail
$100 invested at the start of fiscal 2021 grew to $160, against $201 for the peer group the company picked itself.
- WatchPay only loosely tracked returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
6019thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.20 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.2% of net income
What does the CEO cost owners?
$7.3m pay · $4.5bn net income, FY2025
100100thDetail
$7.3m of reported pay in fiscal 2025, against $4.5bn of net income.
- WatchInsiders are selling
Do they own the stock?
6 mo: ▲ $0 bought · ▼ $60.3m sold
——Detail
10 insiders sold $60.3m in the last six months and none bought. 65 of 96 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −2.3% a year; flagged above +2%
Stock pay 6.9% of revenue
7871stDetail
Diluted shares changed -2.3% a year over the last three fiscal years. Stock-based pay was 6.9% of revenue in the latest year.
- Good2 leadership filings in 3 years
Is leadership stable?
2 filings under 8-K 5.02 in 3 years
CEO: Leonard S. Schleifer
100100thDetail
CEO in the pay table: Leonard S. Schleifer. 2 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 24, 2026.
Pay tied most to stock price
Other key measuresStock PriceRegulatory submissions for new products or indicationsTSRPositive data readoutsNon-GAAP diluted EPSNew Investigational New Drug ApplicationsApprovals of new products or indications
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Leonard S. Schleifer | $7.3m | $39.0m | $7.7m | $160 | $201 | $4.5bn |
| 2024 | Leonard S. Schleifer | $6.8m | −$37.7m | $6.1m | $147 | $156 | $4.4bn |
| 2023 | Leonard S. Schleifer | $8.2m | $141.1m | $6.7m | $182 | $144 | $4.0bn |
| 2022 | Leonard S. Schleifer | $7.0m | $98.8m | $8.1m | $149 | $139 | $4.3bn |
| 2021 | Leonard S. Schleifer | $6.5m | $123.7m | $7.5m | $131 | $124 | $8.1bn |
Insiders and the CEO's stakeSelling
10 insiders sold $60.3m in the last six months and none bought. 65 of 96 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldGeorge L SingDirector$22.3mNov 17, 2026
- SoldAndrew J MurphyCo-Chief Scientific Officer · 10b5-1 plan$8.0mNov 17, 2026
- SoldHuda Y ZoghbiDirector$7.9mNov 3, 2026
- SoldChristine A PoonDirector$7.6mNov 2, 2026
Leadership and governance on file
All 5 filings
- Sep 30, 2026Leadership change8-K 5.02
- Jan 31, 2024Leadership change8-K 5.02
- Sep 8, 2023Leadership change8-K 5.02
- Apr 17, 2023Leadership change8-K 5.02
- Oct 3, 2022Leadership change8-K 5.02
Latest shareholder vote results: Jun 17, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $12.4bn returned to owners in buybacks and dividends, 49% of net income, and $4.2bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $16.1bn | $12.2bn | $13.1bn | $14.2bn | $14.3bn |
| Net income | $8.1bn | $4.3bn | $4.0bn | $4.4bn | $4.5bn |
| Stock-based pay | $601.7m | $725.0m | $885.0m | $982.8m | $993.7m |
| Buybacks | $1.6bn | $2.1bn | $2.2bn | $2.6bn | $3.4bn |
| Dividends | — | — | $0 | $0 | $370.3m |
| Diluted shares | 112m | 114m | 114m | 115m | 109m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.